The improvement in the survival of patients with chronic myeloid leukemia (CML) together with the life-long treatments required with tyrosine kinase inhibitors (TKI) can lead to a great impact on healthcare direct costs.

In this setting, evidence from real life is needed to estimate the financial burden in patients treated with TKIs at later lines with long-term exposure.

A high economic burden for patients with CML in later lines beyond the costs of specific TKI therapy was found, primarily driven by hospitalizations expenditure, suggesting a high level of comorbidity in these patients.